In addition, the company will provide storage and distribution services for Moderna’s Phase III clinical trial of the vaccine candidate.
Catalent chair and CEO John Chiminski said: “Catalent’s proven expertise in manufacturing scale-up and commercial production are well suited to support Moderna’s efforts to prepare for wide-scale supply of this vaccine candidate so that it is available if appropriate to address the pandemic.” How optimistic are you about your company’s growth prospects?View ResultsCatalent’s 875,000ft2 biologics facility in Bloomington will carry out this vial filling work using barrier isolator technology.